2nd$How$to$Diagnose$and$Treat$
LYMPHOMA
November$6<8,$2020
!DISCLOSURES
M. ANDRE Abbvie Scientific1Advisory1Bd.
Amgen Research1Support,1Other
BristolAMyersASquibb Scientific1Advisory1Bd.,1Other
Celgene Research1Support,1Other
Gilead Scientific1Advisory1Bd.,1Other
Johnson1&1Johnson Research1Support
Karyopharm Scientific1Advisory1Bd.
Novartis Scientific1Advisory1Bd.,1Research1Support
Roche1 Research1Support,1Other
Seattle1Genetics Scientific1Advisory1Bd.
Takeda Scientific1Advisory1Bd.
S. ANSELL BristolAMyersASquibb Research1Support
Seattle1Genetics Research1Support
Regeneron Research1Support
AI1Therapeutics Research1Support
Trillium Research1Support
Affimed Research1Support
ADC1Therapeutics Research1Support
E. BACHY Takeda Research1Support,1Other
Janssen Consultant,1Other
Roche1 Advisory1Bd.
Amgen Other
Kite/Gilead Other
Novartis Other
Beigene Other
R. BRENTJENS Gracell1Biotechnologies1Inc Consultant
Juno1Therapeutics Research1Support
C. BUSKE not$received
E. CAMPO Celgene Speakers’1Bureau
Gilead N/A
Illumina Scientific1Advisory1Bd.
Janssen Speakers’1Bureau
Nanostring Scientific1Advisory1Bd.,1Other
Roche Consultant
Takeda Scientific1Advisory1Bd.
J.1J. CASTILLO Abbvie Research1Support,1Consultant
Amgen Research1Support
Beigene Research1Support,1Consultant
Janssen Research1Support,1Consultant
Kymera Research1Support
Pharmacyclics Research1Support,1Consultant
Roche Research1Support
TG1Therapeutics Research1Support
F. D'AMORE Kyowa1Kirin Scientific1Advisory1Bd.
Takeda Scientific1Advisory1Bd.
Servier Research1Support
R. DALLA1FAVERA Akamara1Therapeutics1Inc. Consultant,1Scientific1Advisory1Bd.
Neo1Genomics Consultant,1Scientific1Advisory1Bd.
G. DAMAJ Takeda Research1Support,1Scientific1Advisory1Bd.
Pfizer Research1Support
Hoffmann1A1Roche Scientific1Advisory1Bd.
A. DAVIES Celgene Research1Support,1Scientific1Advisory1Bd.,1Other
Roche Research1Support,1Consultant,1Scientific1Advisory1Bd.,1Other
Gilead/Kite1Pharma Research1Support,1Scientific1Advisory1Bd.
Incyte Scientific1Advisory1Bd.
Regeneron Scientific1Advisory1Bd.
BioInvent Research1Support
ADC1Therapeutics Research1Support,1Scientific1Advisory1Bd.
Acerta1Pharma/AstraZeneca Research1Support,1Scientific1Advisory1Bd.
Karyopharm Research1Support,1Scientific1Advisory1Bd.
Takeda Scientific1Advisory1Bd.
Janssen Research1Support,1Scientific1Advisory1Bd.
A. DOGAN Roche Research1Support
Takeda Research1Support,1Consultant
EUSA1Pharma Consultant
Seattle1Genetics Consultant
PER Consultant
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES